Skip to main content

Table 2 Clinical characteristics by type of microorganisma

From: Clinical characteristics and treatment outcomes in a cohort of patients with pyogenic and amoebic liver abscess

 

None (n = 51)

Enterobacteriaceae including E. coli (n = 35)

Klebsiella (n = 21)

S. milleri (n = 19)

Other Strep spp. (n = 7)

Anaerobe (n = 16)

Other (n = 13)

Amoebic (n = 9)

p-valueb

Abscess

 Number of abscesses

1

27 (52.9%)

19 (54.3%)

13 (61.9%)

12 (63.2%)

5 (71.4%)

8 (50.0%)

6 (46.2%)

7 (77.8%)

p = 0.80

2+

24 (47.1%)

16 (45.7%)

8 (38.1%)

7 (36.8%)

2 (28.6%)

8 (50.0%)

7 (53.9%)

2 (22.2%)

 Max diameter

(cm)

5.4 (3.9, 7.5)

6.0 (4.3, 8.0)

8.0 (5.3, 9.0)

8.5 (5.7, 12.0)

8.0 (6.8, 10.0)

6.0 (3.3, 7.5)

7.3 (5.6, 8.3)

7.3 (5.8, 8.8)

p = 0.04

 Loculated

Yes

15 (29.4%)

15 (42.9%)

11 (52.4%)

10 (52.6%)

4 (57.1%)

3 (18.8%)

7 (53.9%)

1 (11.1%)

p = 0.09

 Resistancec

Yes

–

26 (74.3%)

15 (71.4%)

3 (15.8%)

1 (14.3%)

2 (12.5%)

7 (53.9%)

–

p < 0.001

Other pathologyd

 None

32 (62.8%)

20 (57.1%)

17 (81.0%)

13 (68.4%)

5 (71.4%)

10 (62.5%)

7 (53.9%)

9 (100.0%)

p = 0.52

 Biliary malignancy

4 (7.8%)

2 (5.7%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

1 (6.3%)

0 (0.0%)

0 (0.0%)

 Non-malignant biliary

4 (7.8%)

6 (17.1%)

1 (4.8%)

2 (10.5%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

 Non-malignant GI

10 (19.6%)

6 (17.1%)

2 (9.5%)

4 (21.1%)

2 (28.6%)

4 (25.0%)

6 (46.2%)

0 (0.0%)

 Other cancer

1 (2.0%)

1 (2.9%)

1 (4.8%)

0 (0.0%)

0 (0.0%)

1 (6.3%)

0 (0.0%)

0 (0.0%)

Biochemistry on admission

 WBC (× 109/L)

14.8 (10.8, 17.1)

16.6 (12.2, 21.7)

14.8 (12.9, 16.9)

16.0 (12.9, 20.0)

16.4 (10.6, 21.3)

14.6 (10.6, 20.3)

14.5 (10.5, 19.3)

16.5 (13.9, 19.2)

p = 0.61

 Neutrophils (×109/L)

11.9 (8.0, 13.9)

14.5 (8.9, 19.3)

13.0 (9.9, 14.3)

13.8 (11.3, 19.3)

13.1 (8.4, 13.5)

12.9 (8.5, 18.8)

12.3 (8.9, 17.5)

12.9 (9.3, 14.6)

p = 0.52

 Hb (g/L)

117 (102, 134)

109 (96, 128)

110 (106, 121)

113 (101, 131)

105 (100, 120)

107 (100, 129)

105 (99, 141)

128 (118, 130)

p = 0.62

 CRP (mg/L)

215 (106, 279)

204 (69, 286)

228 (150, 276)

223 (119, 286)

245 (138, 333)

188 (90, 258)

173 (78, 263)

260 (207, 408)

p = 0.40

 INR

1.20 (1.04, 1.44)

1.30 (1.10, 1.40)

1.20 (1.17, 1.45)

1.22 (1.10, 1.48)

1.30 (1.12, 1.40)

1.12 (1.00, 1.40)

1.12 (1.10, 1.45)

1.17 (1.07, 1.30)

p = 0.59

 ALT (IU/L)

44 (20, 104)

35 (15, 69)

78 (48, 143)

30 (24, 46)

47 (20, 132)

43 (22, 115)

76 (48, 141)

40 (25, 65)

p = 0.003

 ALP (IU/L)

146 (91, 252)

170 (98, 268)

186 (118, 297)

168 (111, 250)

237 (62, 319)

158 (105, 228)

297 (105, 319)

156 (125, 225)

p = 0.79

 BILI (umol/L)

15 (10, 24)

20 (11, 35)

20 (11, 45)

16 (9, 29)

9 (9, 61)

14 (11, 44)

34 (10, 77)

16 (11, 17)

p = 0.66

  1. aOf the 141 patients, 51 patients had no microorganism isolated, 81 had 1 or more bacterial spp. (120 in total) and 9 patients had amoebic liver abscesses
  2. bFor continuous measures, F statistic comparing Somer’s D parameters for association of measure with organism type, adjusted for clustering within patients; for categorical variables, Fisher’s exact test
  3. cResistance detected to one or more antimicrobial agents; overall, resistance was detected in 54/111 (48.7%) of isolated microorganisms
  4. dBiliary Malignancies (cholangiocarcinoma); other biliary pathology (gallstones, cholangitis/cholecystitis); Non-malignant GI pathology (diverticulitis, fistula, portal vein thrombosis); Other cancer (metastatic melanoma, colorectal cancer, pancreatic cancer)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us